Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.

By KATIE THOMAS from NYT Health Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy. https://ift.tt/2YPZ7N5